Partnering with the Cosmetic Ingredient Review program to formalize cosmetic-ingredient safety assessments would be "inappropriate," potentially raising "significant appearance concerns and resource issues," according to FDA's fiscal 2017 budget justification.
In reports supporting FY 2016 spending bills, Senate and House appropriations committees proposed transferring CIR to the US Pharmacopeial Convention...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?